Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 14 at 2:00 PM ET

Register Free →
CLEATUS
Get CLEATUS

Collaborative Awards to Support Microphysiological System Pilot Studies in Type 2 Diabetes Research

Active
Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Institute of Diabetes and Digestive and Kidney Diseases, under the Department of Health and Human Services, plans to issue a Notice of Funding Opportunity for research focusing on microphysiological systems to model type 2 diabetes. This initiative aims to leverage advances in biomaterials, microfluidics, and tissue engineering to create three-dimensional cell cultures that simulate physiological tissue organization. The primary goal is to support small pilot and feasibility studies that generate preliminary data on metabolic tissue crosstalk, the basic mechanisms of human type 2 diabetes, and various prevention and treatment strategies. While applications are not currently being accepted, this forecast serves as a notification for potential applicants to establish collaborations across bioengineering, human metabolism, and diabetes biology. The program emphasizes the utility of these systems in investigating the heterogeneity of clinical responses and biological variations in type 2 diabetes. Interested parties should coordinate with the designated point of contact, Albert J. Hwa, to prepare responsive projects for the upcoming solicitation.

General Info

Funding opportunity for pilot studies using microphysiological systems to model type 2 diabetes.

Agency

Department Of Health And Human Services → National Institutes Of Health

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health
Contacts1 person available
OfficeUSA
Organization / AgencyDepartment Of Health And Human Services → National Institutes Of Health
Office AddressUSA
Contacts
Albert J. Hwa PhD
contact@example.gov
+1 (555) 000-0000

Full Description

Show more

The National Institute of Diabetes and Digestive and Kidney Diseases intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for research on microphysiological systems (MPSs) to model type 2 diabetes. Advances in biomaterials, microfluidics, and tissue engineering have resulted in MPSs that allow for greater control of three-dimensional cell cultures containing multiple cell types and constituting more physiological tissue organization. The utility of these systems lends themselves to powerful in vitro modeling of metabolic tissue crosstalk, study of basic mechanisms of human type 2 diabetes, and the testing of prevention and treatment strategies. MPSs are especially useful for investigating the heterogeneity of human T2D biology and clinical responses. The current initiative will support small pilot studies to conceptualize aspects of T2D biology for modeling with MPSs, to support feasibility studies, and to generate preliminary data. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Collaborative investigations combining expertise in bioengineering, type 2 diabetes biology, and human metabolism will be encouraged and these investigators should begin considering applying for this application. 

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Grant
High-Throughput Functional Genomic AssayingThis subcontract, titled High-Throughput Functional Genomic Assaying, supports National Institutes of Health and NHGRI research projects by providing experimental testing of genomic variants. The scope of work involves implementing high-throughput assays to perturb variants and executing functional interpretation strategies utilizing CRISPR-based systems and high-throughput screening platforms. The selected provider is responsible for delivering raw molecular and cellular data along with all associated metadata. The project is managed under the Department of Health and Human Services and requires strict adherence to 45 CFR Part 46 regulations regarding human subjects research. The opportunity was posted on October 9, 2026, with a response deadline of December 14, 2026. It is categorized under NAICS code 541714 for research and development in biotechnology.
National Institutes Of Health

POSTED

4 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Grant
Specialized Phenotypic Assay Development/ExecutionThis subcontract, titled Specialized Phenotypic Assay Development/Execution, supports prime contractors on NIH IGVF Consortium projects under the Department of Health and Human Services. The primary objective is the collection of robust phenotypic data through the execution of imaging, proteomics, and transcriptomics assays designed to measure the impacts of variant interactions. To achieve this, the contractor will utilize advanced technical equipment, including mass spectrometers, flow cytometers, and high-content imaging systems. The scope of work emphasizes the delivery of high-quality phenotypic data sets while adhering to strict quality control standards for high-throughput data. This opportunity falls under NAICS code 541714 and was posted on October 9, 2026, with a response deadline of December 14, 2026.
National Institutes Of Health

POSTED

4 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Grant
Senescence-Specific Reagent and Tool ManufacturingThis subcontract, titled Senescence-Specific Reagent and Tool Manufacturing, supports National Institutes of Health projects focused on senescence technologies. The selected provider will develop and supply innovative reagents, biospecimens, and tools for prime contractors, specifically focusing on the creation of markers for phenotypic identifiers and the manufacture of reagents to identify senescence heterogeneity within secretomes and tissue environments. The scope of work requires the use of biotechnology laboratory facilities for antibody production and protein synthesis, with a final delivery of validated assays and physical reagents. All operations must strictly adhere to NIH guidelines regarding human systems. The opportunity was posted on October 9, 2026, with a response deadline of November 23, 2026, falling under NAICS code 541714.
National Institutes Of Health

POSTED

4 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Grant
Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
Solicitation # RFA-RM-27-007
The National Institutes of Health, under the Department of Health and Human Services, is soliciting the development or adaptation of innovative senescence technologies (SenTecs) through solicitation RFA-RM-27-007. These technologies aim to identify, characterize, and understand senescent cell heterogeneity within tissue environments and secretomes to improve strategies for modulating these cells in human aging and disease. The program utilizes a five-year, milestone-driven award structure divided into two phases: a two-year UG3 phase focused on development and feasibility, and a three-year UH3 phase dedicated to optimization, refinement, and validation. Transition to the UH3 phase is not automatic and requires an administrative review at the end of year two. The final year of the award requires a collaborative demonstration project within the SenNet consortium. The NIH intends to commit 5.4 million dollars in total costs for fiscal year 2027 to fund up to nine awards, with direct cost caps of 400,000 dollars per year for the UG3 phase and 550,000 dollars per year for the UH3 phase. Applications are evaluated based on the importance of the research, scientific rigor, feasibility, and the expertise of the investigators. Required submissions include an Intellectual Property Strategy and a Data Management and Sharing Plan. Awardees must adhere to strict cybersecurity incident reporting, maintain a seven-year confidentiality agreement for non-public information, and ensure all technical assets and data are deposited into the SenNet Data Portal. Clinical trials are not allowed under this specific opportunity.
National Institutes Of Health

POSTED

4 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Grant
IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed)
Solicitation # RFA-HG-27-008
The National Human Genome Research Institute (NHGRI), under the Department of Health and Human Services, is soliciting applications for the Impact of Genomic Variation on Function (IGVF) Data and Coordinating Center (DACC) via solicitation RFA-HG-27-008. The DACC will serve as the central hub for the IGVF Consortium, tasked with developing a comprehensive, searchable catalog of genomic function and variant impacts and managing a data portal for housing and sharing consortium resources. Key technical objectives include the hardening of data processing pipelines to ensure they are containerized, robust, and reproducible, while adopting existing data and metadata standards to promote interoperability. The NHGRI intends to commit 6 million dollars in total costs for the period of FY 2027-2031, with annual application budgets limited to 4 million dollars in direct costs. Funding decisions are based on scientific peer review and program-specific considerations, focusing on technical merit, synergy with other IGVF projects, and the applicant's capability to coordinate large-scale genomic data efforts. Applicants must maintain active registrations in SAM, eRA Commons, and Grants.gov, and all Principal Investigators must have a linked ORCID ID. Special requirements include a dedicated Project Manager devoting at least 6 person months and strict adherence to the Cybersecurity Act of 2015, which mandates reporting cybersecurity incidents within 48 hours of discovery. Proposals must include a Research Strategy limited to 30 pages and be submitted via an institutional system-to-system solution by the December 14, 2026, deadline.
National Institutes Of Health

POSTED

4 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Grant
Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)
Solicitation # RFA-RM-27-016
The National Institutes of Health (NIH) is soliciting applications under RFA-RM-27-016 to establish SenNet Discovery and Validation Centers (DVCs) as part of Stage 2 of the Cellular Senescence Network. The primary objective of these centers is to define, refine, and validate tissue- and disease-relevant cellular senescence signatures, known as senotypes, and their associated biomarkers. DVCs are required to investigate the functional consequences of these signatures in human health and disease, generate high-quality molecular, cellular, and spatial datasets for public release via the Data Coordination and Informatics Center, and execute consortium-wide organizational and outreach activities. The maximum project period is five years, with application budgets limited to approximately 3 million dollars in direct costs per year. A specific requirement includes a mandatory 600,000 dollar annual direct cost allocation for the SenNet Organization and Outreach Component, of which 40 to 45 percent must support educational programs. Additionally, starting in Year 2, centers must set aside approximately 10 percent of their total budget for cross-consortium validation. Applications are evaluated through the NIH peer review system based on significance, approach, and the protection of human subjects, with performance measured annually by the successful acceptance and public release of data. Applicants must maintain active registrations in the System for Award Management and eRA Commons. Required submission materials include a 30-page application divided into four elements covering vision, preclinical modeling, biospecimen management, and outreach, along with letters of support and human subjects documentation where applicable. Awardees must adhere to strict data security protocols, including a seven-year confidentiality disclosure agreement and a requirement to report cybersecurity incidents within 48 hours.
National Institutes Of Health

POSTED

4 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Grant
Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants on Genome Function and Phenotype (UM1 Clinical Trials Not Allowed)
Solicitation # RFA-HG-27-007
The National Institutes of Health, through the Department of Health and Human Services, is soliciting applications under RFA-HG-27-007 to establish centers for the Impact of Genomic Variation on Function (IGVF) Consortium. The primary objective is to characterize genomic variation and assess how individual variants in DNA, RNA, or protein-coding elements impact genome function and phenotypes. Funded centers will utilize high-throughput methods to perturb variants, collect molecular and cellular data, and develop portable data processing pipelines. These centers are expected to collaborate within the consortium to coordinate assays and cell types, contributing raw and processed data to the IGVF Catalog via the Data Analysis and Coordination Center. The funding cycle runs from 2027 through fiscal year 2031, with a maximum project period of five years and budgets limited to 2 million dollars in direct costs per year. Notably, 20 percent of direct costs must be allocated to support collaborative work. Applications are evaluated based on scientific merit through the NIH peer review system and a second level of review by the National Advisory Council for Human Genome Research, focusing on significance, overall impact, and the utility of the proposed assays. Clinical trials are not allowed, and research involving human subjects must comply with 45 CFR Part 46. Applicants must maintain active registrations in the System for Award Management and eRA Commons, and all Principal Investigators must have a linked ORCID ID. Required submissions include a Research Strategy limited to 30 pages, a Resource Sharing Plan, and a Data Management and Sharing Plan. Key personnel requirements include a minimum of three person-months of effort for the PD/PI and a dedicated Project Manager committing at least four person-months. Additionally, awardees must implement a cybersecurity incident response plan with a 48-hour notification requirement for any discovered incidents.
National Institutes Of Health

POSTED

4 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Grant
Genomic Variant Interactions With Other Variants Or The Environment (UM1 Clinical Trials Not Allowed)
Solicitation # RFA-HG-27-009
Solicitation RFA-HG-27-009 is a Notice of Funding Opportunity from the National Institutes of Health, under the Department of Health and Human Services, for a UM1 Research Project with Complex Structure Cooperative Agreement. The program seeks to establish interaction centers to study how genetic or environmental interactions modify genomic variant impact as part of the second phase of the Impact of Genomic Variation on Function (IGVF) Consortium. Awardees must develop a quantitative research framework to detect joint effects beyond additive modifiers, apply genomic perturbation methods to collect phenotypic data, and share all resulting data, analyses, and predictive methods through the IGVF portal and catalog. The initiative is designed as discovery science to improve the understanding of genome-wide association studies and polygenic scores. Eligible applicants include small businesses and other for-profit organizations, with a maximum project period of five years and a budget limit of 1.5 million dollars in direct costs per year. Applications are due by December 14, 2026, and are evaluated via the NIH peer review system based on significance, contribution to consortium goals, and the rigor of the proposed research. Key requirements include a dedicated Project Manager devoting at least four person months and a PD/PI effort of at least three person months. Additionally, awardees must comply with strict cybersecurity incident reporting guidelines, maintain active SAM and eRA Commons registrations, and adhere to federal regulations regarding human subjects and vertebrate animal research.
National Institutes Of Health

POSTED

4 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Grant
Computational Modeling and Analysis of the Impact of Genomic Variation on Function (UM1, Clinical Trial Not Allowed)
Solicitation # RFA-HG-27-010
The National Institutes of Health, under the Department of Health and Human Services, is soliciting applications through RFA-HG-27-010 for the Computational Modeling and Analysis of the Impact of Genomic Variation on Function initiative. This UM1 Research Project with Complex Structure Cooperative Agreement seeks to establish centers that will join the Impact of Genomic Variation on Function (IGVF) Consortium. The primary objective is to develop, apply, and test interpretable computational models that utilize biological, biochemical, and biophysical mechanistic information to determine how genomic variation affects genome function and phenotypes related to human health. Awardees are expected to produce open-source software, models, and documentation, while sharing predictions and integrative analyses via the IGVF catalog and data portal. The maximum project period is five years, with application budgets limited to 800,000 dollars in direct costs. A critical requirement is that 20 percent of direct costs must be allocated annually to support collaborative work. Personnel requirements include a minimum aggregate effort of three person months for PD/PIs and a dedicated Project Manager devoting at least four person months. Applications are evaluated via the NIH peer review system based on significance, investigators, innovation, approach, and environment, with a focus on the likelihood of exerting a sustained influence on the research field. Eligible applicants include small businesses and other for-profit organizations, provided they maintain active SAM registration and a Unique Entity Identifier. All awards are administered under 42 CFR Part 52 and 2 CFR Part 200.
National Institutes Of Health

POSTED

4 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Grant
Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)
Solicitation # RFA-RM-27-016
The National Institutes of Health is seeking applications for the Cellular Senescence Network Discovery and Validation Centers under solicitation RFA-RM-27-016. This initiative represents Stage 2 of the SenNet program, focusing on the definition, refinement, and validation of tissue- and disease-relevant cellular senescence signatures, known as senotypes, and their associated biomarkers. Selected centers will investigate the functional consequences of these signatures on human health and disease while generating high-quality molecular, cellular, and spatial datasets to be shared with the broader scientific community. Awardees are expected to utilize complementary experimental systems to validate biomarkers and analyze responses to senotherapeutic approaches or senescence-associated perturbations. In addition to research goals, applicants must propose specific aims for consortium-wide organizational and outreach activities. Interested parties must submit their responses by the deadline of November 24, 2026.
Rmod

POSTED

4 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Grant
Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
Solicitation # RFA-RM-27-007
The National Institutes of Health is soliciting proposals for the Cellular Senescence Network through solicitation RFA-RM-27-007 to develop or adapt innovative senescence technologies. These technologies aim to identify, characterize, and understand the biological consequences of senescent cell heterogeneity within tissue environments and secretomes. The ultimate goal is to create novel strategies for modulating these cells in vivo and predicting outcomes for human aging and various disease conditions. These five-year, milestone-driven awards are structured in two distinct phases. The initial two-year UG3 phase focuses on technology development and feasibility, while the subsequent three-year UH3 phase is dedicated to optimization, refinement, and validation, concluding with a collaborative demonstration project within SenNet. Applicants must submit both phases together, though transition to the UH3 phase is contingent upon an administrative review following the second year. Responses are due by November 24, 2026.
Rmod

POSTED

4 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Grant
IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed)
Solicitation # RFA-HG-27-008
The National Human Genome Research Institute is seeking applications for the Impact of Genomic Variation on Function Data and Coordinating Center under solicitation RFA-HG-27-008. The selected center will act as the primary coordinating hub for the IGVF Consortium, focusing on the development and expansion of accessible resources such as a data portal and a searchable catalog of predicted and measured variant impacts. Key responsibilities include facilitating consortium activities, collaborating with other research programs, and gathering community input to refine the catalog's design to accelerate the understanding of genomic variation. This federal solicitation was posted on October 9, 2026, with a response deadline of December 15, 2026. The opportunity is designated as a U24 grant, and clinical trials are not allowed. The project aims to maximize the overall scientific impact of the IGVF Consortium through strategic coordination and the provision of comprehensive genomic data resources.
National Human Genome Research Institute

POSTED

4 days ago

DEADLINE

in 2 months
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health

Same awarding agency

NAICS: 541715
Grant
Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Research Program (U19 Clinical Trial Optional)The National Institute on Alcohol Abuse and Alcoholism, under the Department of Health and Human Services, intends to issue a Notice of Funding Opportunity to continue the Collaborative Initiative on Fetal Alcohol Spectrum Disorders. This multidisciplinary research consortium focuses on a wide range of studies, including basic, clinical, translational, diagnostic, intervention, and prevention research aimed at addressing the lifelong physical, cognitive, and behavioral impairments caused by prenatal alcohol exposure. The program seeks to support high-priority needs such as improving early identification and diagnosis, validating interventions, and exploring the mechanisms of alcohol teratogenesis to reduce the incidence of these disorders. Successful projects must demonstrate strong integration with the broader consortium through the use of shared resources, coordinated data activities, and multidisciplinary expertise. This forecast indicates a research program where clinical trials are optional.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

7 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Centers for Research on Neglected Infectious DiseasesThe National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is establishing the Centers for Research on Neglected Infectious Diseases to combat communicable viral, bacterial, parasitic, and fungal infections. This initiative focuses on the epidemiology, pathogenesis, diagnosis, treatment, and prevention of parasitic neglected infectious diseases within endemic regions. By building sustainable in-country research capacity and expertise, the program aims to identify, contain, and mitigate these diseases at their source to protect global health and reduce the risk of spread within the United States. This opportunity is issued as a forecast by the Department of Health and Human Services and is governed by the Public Health Service Act and Federal Regulations 42 CFR Part 52 and 2 CFR Part 200. Interested parties can coordinate with the Division of Microbiology and Infectious Diseases for further information. The program emphasizes a multidisciplinary approach to research and training to address the substantial morbidity and mortality associated with understudied infectious diseases.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

7 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
HIV Prevention and Alcohol (R61/R33 Clinical Trials Optional)The National Institutes of Health, under the Department of Health and Human Services, is offering a Phased Innovation Award to advance innovative HIV prevention interventions. This funding opportunity utilizes a two-stage R61/R33 structure to move research from initial development and feasibility testing to larger-scale efficacy and implementation studies. The initial R61 phase focuses on the development, refinement, and pilot testing of novel strategies to address critical scientific and operational questions, ensuring readiness for expanded evaluation across diverse populations. Upon the successful completion of R61 milestones, the R33 phase provides support for expanded testing of interventions and implementation strategies. These studies may evaluate the scalability, sustainability, and clinical management of HIV prevention interventions, specifically including integrated approaches that address alcohol use and related comorbidities. Interested parties can contact the HIV/AIDS and Alcohol Research Program for further information.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

12 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required)The National Institutes of Health is forecasting a Notice of Funding Opportunity to solicit applications for early to definitive clinical trials. This initiative seeks proposals testing a wide range of interventions, including drugs, devices, biologics, procedures, and behavioral or social interventions, provided they align with the research missions of the participating NIH Institutes, Centers, and Offices. The funding will utilize a bi-phasic, milestone-driven R61/R33 activity code with a maximum project period of seven years. The R61 phase focuses on planning activities, while the R33 phase supports the actual clinical trial. Although applications are not currently being accepted, this notice serves as an advance alert for investigators with expertise in trial design, implementation, and stakeholder engagement to begin developing collaborations and projects.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

14 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Continuation of the Exceptional Longevity Data Management and Coordinating Center (EL DMCC) (U24 Clinical Trial Not Allowed)The National Institute on Aging intends to issue a single U24 cooperative agreement award to support the continued operation and expansion of the Exceptional Longevity Data Management and Coordinating Center. Serving as the central hub for human longevity translational research, the center integrates deeply phenotyped cohorts and multi-omics datasets to enable cross-cohort analyses and collaborative research. Key responsibilities include data harmonization, the implementation of common data standards, and the management of the ELITE Portal, which provides the research community with secure access to analytical tools and cloud-based computational workspaces. The upcoming funding opportunity will require the Coordinating Center to expand its capabilities in artificial intelligence, machine learning, and the integration of diverse datasets across different species. Future objectives include the development of curated target knowledgebases for therapeutic targets, the enhancement of portal interoperability according to FAIR data principles, and the strengthening of community engagement through specialized training and workshops. This notice serves as a forecast to allow potential applicants to establish collaborations before the official solicitation is released.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

19 days ago

DEADLINE

N/A
View Details
NAICS: 541714
Grant
Immune Drivers of Autoimmune DiseaseThe National Institute of Allergy and Infectious Diseases seeks to support the Immune Drivers of Autoimmune Disease network to investigate the triggers and early mechanisms of autoimmunity in humans. The primary goal is to develop tools for risk prediction and staging, identify pre-clinical immune mechanisms, and utilize artificial intelligence and big data to prevent autoimmune diseases. This initiative emphasizes the creation of preclinical cohorts and the use of remote recruitment and sampling to advance medical research. The network will be managed by a Coordinating Center responsible for data harmonization, sample sharing, and the administration of an Infrastructure Opportunity Fund for collaborative research projects. This forecast, issued by the National Institutes of Health under the Department of Health and Human Services, establishes a framework for shared infrastructure and steering committee oversight to identify common pathways and prevention opportunities.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

19 days ago

DEADLINE

N/A
View Details
NAICS: 513130
Grant
NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed)The National Institutes of Health, through the Department of Health and Human Services, is soliciting applications for the NLM Grants for Scholarly Works in Biomedicine and Health program. This initiative provides funding for the creation of book-length manuscripts and other integrative scholarly works, such as critical reviews and analytical syntheses, designed to benefit U.S. health professionals, scientists, and public health practitioners. The primary goal is to organize and disseminate biomedical and health-related knowledge to improve research, education, and clinical practice. This opportunity is listed as a forecast with a posted date of September 24, 2026. It specifically prohibits the use of clinical trials. Interested parties can contact the NLM Extramural Programs office for further information regarding the application process and program requirements.
Book Publishers

POSTED

19 days ago

DEADLINE

N/A
View Details
NAICS: 541714
Grant
Partnerships for Advancing Development of Diagnostics for Infectious DiseasesThe National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is seeking to establish partnerships between academic or small business investigators and industrial partners to advance the translational development of diagnostic tests for infectious diseases. This initiative focuses on moving diagnostics that have already demonstrated proof-of-concept through the commercialization process by aligning researchers with experienced industry partners to de-risk development and ensure products are fit for purpose. The program will be supported by a science advisory board and NIAID oversight, incorporating annual meetings and workshops to facilitate collaboration and knowledge exchange. This effort is authorized under the Public Health Service Act and federal regulations to ensure that promising diagnostic technologies are successfully translated into tools for treating and preventing infectious diseases.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

19 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
LeverAging StraTegies to Maximize ImpLementation and Effectiveness for HIV (LAST MILE)The National Institute of Allergy and Infectious Diseases, under the Department of Health and Human Services, is forecasting the LeverAging StraTegies to Maximize ImpLementation and Effectiveness for HIV (LAST MILE) program. This initiative aims to bridge the gap between traditional clinical trial findings and real-world application by supporting collaborations on effectiveness trials, pragmatic trials, and hybrid effectiveness-implementation studies. The program focuses on the prevention and treatment of HIV, including associated coinfections and comorbidities, across all age groups and various points of care. The goal of the program is to advance cross-cutting research in epidemiology, implementation science, and clinical, behavioral, and social sciences. This effort aligns with the broader NIH mission to implement research advances in HIV/AIDS. The opportunity is authorized under the Public Health Service Act and relevant federal regulations, with administrative oversight provided by the Division of AIDS Epidemiology Branch.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

19 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Collaborative Centers in Children’s Environmental Health Research and Translation (P2C Clinical Trial Optional)The National Institutes of Health, under the Department of Health and Human Services, is seeking applications to establish a national network of Children's Environmental Health Research Translation Centers. These centers are designed to protect and improve children's health by developing scientific questions and public health interventions focused on translational research. A primary objective is to move evidence-informed biomedical findings into practical application for the wider community while mentoring a new generation of investigators in the field. Beyond research and translation, the program will function as a national resource to coordinate responses to emerging environmental exposures that impact children. The initiative emphasizes the creation of actionable strategies to prevent harm and ensure a healthy future for children through collaborative efforts within the environmental health community.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

19 days ago

DEADLINE

N/A
View Details
NAICS: 541714
Grant
The Role of the Innate Immune System in the Pathogenesis of Type 1 DiabetesThe National Institute of Allergy and Infectious Diseases, under the Department of Health and Human Services, is forecasting a grant opportunity to investigate the role of the innate immune system in the initiation of Type 1 Diabetes. Funded by the Special Statutory Funding Program for Type 1 Diabetes Research, this initiative seeks to identify genetic and environmental causes of the disease by examining how innate immune components interact with beta cells and pancreatic tissues. The program emphasizes the use of new approach methodologies to determine the timing and impact of environmental triggers that activate these immune pathways. The primary objective is to improve the early identification of high-risk individuals and develop future prevention and therapeutic strategies. This effort is conducted under the authority of the Public Health Service Act and relevant federal regulations. Interested parties can contact the RISP-T1D point of contact for further information regarding this forecast.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

19 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)The National Institute of Neurological Disorders and Stroke (NINDS) is seeking to support scientific research using data from intermediate-size patient population expanded access protocols for Amyotrophic Lateral Sclerosis (ALS). To be eligible, protocols must provide access to an investigational drug or biological product for individuals with ALS and generate data that supports research into the prevention, diagnosis, mitigation, treatment, or cure of the disease. Research goals may include analyzing the effects of products on biomarkers, target engagement, safety and outcome information such as survival and hospitalization, or general patient experience data. This opportunity is currently listed as a forecast by the National Institutes of Health under the Department of Health and Human Services, and applications are not being solicited at this time. The notice serves as a preliminary announcement to allow potential applicants sufficient time to develop responsive projects. Interested parties can contact the ALS Program for further information.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

20 days ago

DEADLINE

N/A
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS